STAT Plus: Lawmakers demand drug makers stop threatening to end discounts for safety-net hospitals
Dozens of U.S. lawmakers sent sharply worded letters to the Trump administration and the pharmaceutical…
Category: STAT Plus
STAT Plus: Compass Pathways set to become the first psychedelic biotech IPO
Compass Pathways isn’t the first company to fashion FDA-regulated therapies out of psilocybin, but it…
STAT Plus: Court rules New York can collect taxes from drug makers to address opioid crisis
A U.S. appeals court upheld a controversial New York state law to require drug makers…
STAT Plus: FDA warns Sprout for failing to mention risks in radio ad for Addyi
The Food and Drug Administration has admonished Sprout Pharmaceuticals for running a radio ad that…
STAT Plus: What will it take for Gilead to break even on its $21 billion deal?
For years, investors have pestered Gilead Sciences with the same question in myriad phrasings: When…
STAT Plus: Pharmalittle: Gates is ‘dumbfounded’ by U.S. Covid-19 response; WHO urges countries to join COVAX
Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy…
STAT Plus: With a detailed rundown, Pfizer seeks to paint a picture of a research turnaround
Pfizer has been making headlines because of its work developing a Covid-19 vaccine. On Monday…
STAT Plus: Pharmalittle: Gilead to pay $21 billion to buy Immunomedics; Trump releases executive order on drug pricing
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Inside Gilead’s $21 billion purchase of Immunomedics: Lamb chops, steak, and a chance for transformation
Key negotiations that helped seal Gilead Science’s $21 billion purchase of Immunomedics, announced Sunday, took…
STAT Plus: How much is a startup worth? For biotech companies, the answer is rarely public
Valuations are fundamental information about any startup. Not only can high valuations give a company…
STAT Plus: A Pennsylvania lawmaker wants to tie prescription drug prices to what Canada pays
In the latest gambit by a state lawmaker to lower prescription drug costs, a Pennsylvania…
STAT Plus: Patent board delivers blow to University of California over its CRISPR invention claims
Making a key ruling in a long-running battle over lucrative patent rights, a government patent…
STAT Plus: Federal judge dismisses lawsuit over patient data sharing by Google and the University of Chicago
A federal judge in Illinois this month dismissed a high-profile lawsuit against Google and the…
STAT Plus: Venture capitalist donates BrainGate, brain-machine interface company, to Tufts University
For more than a decade, scientist and entrepreneur Jeff Stibel’s company BrainGate has been developing…
STAT Plus: Pharmalittle: NIH to test blood thinners against Covid-19; AbbVie employees feel pressured to return to work
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Casma Therapeutics raises another $50 million to target muscular dystrophy
Casma Therapeutics, a Cambridge biotech trying to develop new medicines based on discoveries about how…
STAT Plus: Korro Bio raises $90 million to fix mutations that cause diseases
Korro Bio, a Cambridge biotechnology firm, said Thursday it has raised more than $90 million…
STAT Plus: Pharmalittle: AstraZeneca hopes for Covid-19 vaccine results by year-end; fewer Americans trust the CDC
Hello, everyone, and how are you today? We are just fine, thank you. A cool…
STAT Plus: Is the Covid-19 pandemic a tipping point for digital health?
Covid-19 may turn out to be digital health’s tipping point, two Silicon Valley venture capitalists…
STAT Plus: U.S. Postal Service changes continue to slow down deliveries of mail-order prescriptions
When it comes to delivering prescription drugs to Americans, the U.S. Postal Service may as…
STAT Plus: Liquid biopsy startup Grail files for an IPO
Liquid biopsy company Grail has filed for a $100 million initial public offering, according to…
STAT Plus: Pharmalittle: AstraZeneca pauses its Covid-19 vaccine trial; FDA sticking with its vaccine approval guidelines
Rise and shine, everyone, another busy day is on the way. Our first clue is…
STAT Plus: Can AI improve cancer diagnosis in real patients? Google has enlisted the U.S. military to find out
Google has published plenty of papers demonstrating the potential of artificial intelligence to detect cancer…
STAT Plus: Drug and device makers paid teaching hospitals $832 million in 2018, creating potential for conflicts of interest
Amid ongoing concern that drug and device makers may influence medical practice and research, a…
STAT Plus: Dan Trigub, head of Uber Health, is leaving to launch a health care startup
Dan Trigub, who for the last two years has led Uber Health, is leaving the…
STAT Plus: Pharmalittle: Covid-19 vaccine makers pledge to prioritize safety and efficacy; is Operation Warp Speed working?
Good morning, everyone, and nice to see you again after a long holiday break on…
STAT Plus: Merck chronic cough drug shows mixed results in late-stage clinical trials, raising questions about its future
An experimental pill from Merck reduced the frequency of chronic coughing enough to achieve the…
STAT Plus: ‘An unchartered situation for all of us’: From shipping containers to security concerns, a Covid-19 vaccine supply chain takes shape
For the past few months, Joachim Kuhn has scrambled to rework his factories and rapidly…
STAT Plus: Plasma giant Grifols to buy Silicon Valley startup targeting blood proteins for age-related diseases
The giant blood plasma processing company Grifols on Monday said it has agreed to buy…
STAT Plus: Blueprint Medicines wins U.S. approval for genetically targeted lung cancer drug
The Food and Drug Administration on Friday approved a new drug from Blueprint Medicines for…
STAT Plus: A second U.S. agency will review if Moderna disclosed federal funding in vaccine patents
A second U.S. government agency is now reviewing whether Moderna (MRNA) properly disclosed millions of…
STAT Plus: ‘The race is on’: China’s I-Mab gets boost from AbbVie to develop a new cancer immunotherapy
HONG KONG — In November 2014, a little less than six years ago, Chinese scientist…
STAT Plus: Pharmalittle: Slaoui vows to quit OWS if politics trumps vaccine science; do we have enough freezers?
Good morning. Elizabeth Cooney here, taking the wheel from Ed Silverman today as we ponder…
STAT Plus: Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?
Most biotech startups are free to tell the world as little or as much as…
STAT Plus: Biofourmis raises $100 million for remote patient monitoring tools
Biofourmis, a Boston startup that makes technology to remotely monitor patients with chronic conditions and…
STAT Plus: Amarin loses appeal over heart drug patent, dashing its commercial hopes
Amarin failed to convince a federal appeals court to revive key patents covering its heart…
STAT Plus: Pharmalittle: States asked to speed Covid-19 vaccine distribution sites; NIH panel contradicts FDA on plasma
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT Plus: How Trump could use a rare regulatory maneuver to lower drug prices before Election Day, and how it could backfire
WASHINGTON — The final two months before a presidential election don’t typically feature much policymaking,…
STAT Plus: Pharmalittle: U.S. won’t join WHO Covid-19 vaccine program; experts say a vaccine is possible this fall
Top of the morning to you, and a fine one it is. Despite the gray…
STAT Plus: You had questions about precision medicine. Stanford’s Lloyd Minor has answers
Precision medicine is seen by many as the next frontier in health care. Stanford Medicine,…
STAT Plus: What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings
Last week, two virtual care providers filed paperwork to go public — offering an unprecedented…
STAT Plus: FDA cites Mylan for ‘repeated failures’ at manufacturing plants in India
For the second time in less than a year, the Food and Drug Administration has…
STAT Plus: Congressional committee to subpoena AbbVie in drug pricing investigation
A Congressional committee plans to subpoena AbbVie (ABBV) for documents about pricing practices for two…
STAT Plus: In research on middle-aged mice, scientists find a metabolite that leads to a longer, healthier life
The field of aging research is increasingly asking not just how people can live longer,…
STAT Plus: Pharmalittle: Sanofi drug fails to tackle serious Covid-19 cases; EC agrees to fund WHO Covax program
Rise and shine, everyone, another busy day is on the way. Summertime may still be…
STAT Plus: Small vape makers seek another extension on a looming FDA application deadline, sparking battle with advocates
WASHINGTON — Vaping companies have just nine days until they must submit formal marketing applications…
STAT Plus: Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs
Amid a national outcry over the cost of insulin, one of the largest generic companies…
STAT Plus: Coalition urges Justice Department to seek criminal charges against opioid executives
A coalition of advocacy groups and families is asking the Department of Justice to pursue…
STAT Plus: Pharmalittle: FDA is willing to fast-track a Covid-19 vaccine; most Americans worry politics drives vaccine approval process
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Aimmune Therapeutics, maker of peanut allergy treatment, will be acquired by Nestle
Aimmune Therapeutics, maker of a peanut allergy treatment, said Monday that it will be acquired…